![]() | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H26O11 |
Molar mass | 418.395 g·mol−1 |
3D model (JSmol) | |
| |
|
Tegomil fumarate is an experimental medication under investigation for the treatment of relapsing remitting multiple sclerosis. [1]
The mechanism of action of tegomil fumarate is not fully understood but it is thought to act via its main active metabolite monomethyl fumarate. [1] This metabolite activates the NRF2 transcriptional pathway, which reduces inflammation and modulates the activity of immune cells, thereby protecting the cells of the central nervous system from damage. [1]
In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Riulvy, intended for the treatment of adults and children from 13 years of age with relapsing remitting multiple sclerosis. [1] The applicant for this medicinal product is Neuraxpharm Pharmaceuticals, S.L. [1] Riulvy is a hybrid medicine of Tecfidera, which has been authorized in the EU since January 2014. [1] Riulvy contains a different active substance but acts via the same active metabolite as Tecfidera, monomethyl fumarate. [1]
Tegomil fumarate is the international nonproprietary name. [2]